<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>The management of <z:hpo ids='HP_0002020'>gastroesophageal reflux disease</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">GERD</z:e>) has advanced dramatically in the past 20 years because of increased understanding of its pathophysiology and improvements in available treatments </plain></SENT>
<SENT sid="1" pm="."><plain>A number of important new ideas arousing controversy include the place of over-the-counter <z:chebi fb="0" ids="37961">H2 receptor antagonists</z:chebi>; the role of endoscopy in diagnosis of reflux symptoms; initial treatment options with regard to stepping up therapy to the most effective as needed or stepping down therapy from a <z:chebi fb="0" ids="49200">proton pump inhibitor</z:chebi> given initially because of its superior efficacy in <z:hpo ids='HP_0000001'>all</z:hpo> grades of reflux disease; the optimal choice of long term management of patients with <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">GERD</z:e> or <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">GERD</z:e> complicated by Barrett's <z:mpath ids='MPATH_160'>metaplasia</z:mpath>; the risk of Barrett's <z:mpath ids='MPATH_160'>metaplasia</z:mpath>; and the role of surveillance of this population </plain></SENT>
<SENT sid="2" pm="."><plain>This paper reviews these topics and addresses the controversial issues </plain></SENT>
</text></document>